Yonhap Infomax NewsFeb 5
South Korea's stock issuance value jumped 45.5% to KRW 35.8 trillion in 2025, despite a sharp drop in volume, driven by paid-in capital increases and strong activity from KOSPI-listed firms.
#YonhapInfomax #StockIssuance #KoreaSecuritiesDepository #KOSPI #PaidInCapitalIncrease #ConvertibleBonds #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103939
Stock Issuance in South Korea Surged 45.5% to KRW 35.8 Trillion in 2025 Despite Volume Decline

South Korea's stock issuance value jumped 45.5% to KRW 35.8 trillion in 2025, despite a sharp drop in volume, driven by paid-in capital increases and strong activity from KOSPI-listed firms.

Yonhap Infomax
Yonhap Infomax NewsDec 26
Lotte Hotel Co. will invest 214.4 billion won ($164 million) for a 19.07% stake in Lotte Biologics, as Lotte Group ramps up support for its biopharma business through new funding initiatives.
#YonhapInfomax #LotteHotel #LotteBiologics #EquityInvestment #HybridSecurities #PaidInCapitalIncrease #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=97303
Lotte Hotel to Invest in Lotte Biologics Stake—Holding Company Signals Further Support

Lotte Hotel Co. will invest 214.4 billion won ($164 million) for a 19.07% stake in Lotte Biologics, as Lotte Group ramps up support for its biopharma business through new funding initiatives.

Yonhap Infomax
Yonhap Infomax NewsNov 14
ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.
#YonhapInfomax #ABLBio #EliLilly #PaidInCapitalIncrease #TechnologyTransfer #ADCPlatform #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90894
ABL Bio Shares Surge on Decision for Paid-In Capital Increase Targeting Eli Lilly

ABL Bio shares jumped over 10% after announcing a paid-in capital increase targeting Eli Lilly, following a $2.6 billion ADC platform licensing deal, signaling strengthened partnership and investor confidence.

Yonhap Infomax